News Headlines

  1. Vector Science & Therapeutics Corp., LyoGenesis Plus And Wynn Pharmaceuticals Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products 7/28/2026

    LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp. ("Vector"), and Wynn Pharmaceuticals LLC ("Wynn") today announced they have entered into a Memorandum of Understanding (MOU) to collaborate on the development and manufacture of a new line of IV bag and vial adaptor products.

  2. AGC Biologics Lands Commercial Manufacturing Agreement For Yokohama Site Worth Hundreds Of Millions Of Dollars 7/28/2026

    Ahead of the official opening of AGC Biologics’ Yokohama site, an international biopharmaceutical company has already secured half of the facility’s mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. 

  3. Celonic AG And Leukocare AG Announce Development Collaboration To Support Joint Clients With Complex Biologics And Advanced Drug Product Profiles 7/28/2026

    Celonic AG, a Swiss-based biologics Contract Development and Manufacturing Organization (CDMO), and Leukocare AG, a leading provider of drug product development services, today announced a collaboration to support biopharmaceutical companies developing increasingly complex biologics.

  4. ProBioGen And VarmX B.V. Announce Collaboration For Advanced Cell Line Development 7/28/2026

    ProBioGen today announced a new collaboration with VarmX B.V. for the development of their second therapeutic Factor X candidate. The partnership will advance VarmX's innovative Factor X program through cell line development using ProBioGen's proprietary HEK293 host cell line platform.

  5. Idorsia Advances Global Rollout Of QUVIVIQ With Jamjoom Pharma Partnership In Saudi Arabia And The Levant 7/27/2026

    Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region.

  6. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.

  7. Vimy Pharmaceuticals, KITAM Science, And ABCHealth Partner To Open A Quality-Assured Medicines Corridor Into Africa 7/24/2026

    Vimy Pharmaceuticals Inc., a Canadian pharmaceutical company, and KITAM Science Inc., a convergent-AI trade-intelligence company, alongside ABCHealth, the African Business Coalition for Health, today announced a partnership to establish a quality-assured pathway for Vimy Pharma's essential medicines into African markets, beginning with an initial pilot.

  8. Natoli Engineering Announces Acquisition Of Scheu & Kniss 7/23/2026

    Natoli Engineering Company, Inc., a global leader in tablet compression tooling, replacement parts, tablet presses, and technical services, today announced the acquisition of Scheu & Kniss, a company with more than a century of experience providing tablet press replacement parts, turret manufacturing, machine rebuilding, and technical support to the pharmaceutical, nutraceutical, confectionery, and industrial tablet manufacturing industries.

  9. Théa And Unither Launch New Ophthalmic Production Facility 7/23/2026

    Théa, an independent family-owned pharmaceutical group specialized in the development and commercialization of ophthalmic treatments, and Unither Pharmaceuticals, a French pharmaceutical development and manufacturing company, announce the signing of a long-term strategic industrial partnership aimed at supporting Théa Group’s growth in Europe.

  10. Bora Pharmaceuticals And Onconic Therapeutics Sign Manufacturing Agreement To Support U.S. Clinical Development Of JAQBO Tablets 7/23/2026

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, and Onconic Therapeutics, a Korea-based biopharmaceutical company, have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO potassium-competitive acid blocker tablets, or P-CAB, treatment for GERD, which affects approximately 20% of the U.S. population. As treatment needs continue to evolve, P-CAB therapies are gaining attention for their rapid and sustained acid suppression profile.